Clinical trials: Botulinum Toxin Injection
Injection Site Discomfort
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
- Trial name
- NCT06161246
- Testing
- Vibrating Beauty Bar
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Upper Limb Spasticity
Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice
The primary purpose for this study is to understand the effect of botulinum toxin as a treatment integrated in the management of spasticity (stiffness) in the arm and/or hand, arising from any neurological condition.
- Trial name
- ULIS III (NCT02454803)
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 1,004 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.
- Trial name
- NCT02303002
- Testing
- Botulinum Toxin Type A, Active Comparator botulinum toxin
- Where
- Canada
- Volunteers
- 268 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.
Habitual Snoring
Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring
The purpose of this study is to identify out of up to three doses a safe and effective dose of Botulinum toxin type A for an injection into one side of the soft palate to treat snoring.
- Trial name
- NCT01515371
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Low Back Pain
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients…
- Trial name
- NCT00246155
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ipsen
Upper Facial Lines
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities…
- Trial name
- UFL BOND 974 (NCT06218251)
- Testing
- BOTOX
- Where
- 10 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines.
- Trial name
- NCT06583486
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 488 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Moderate to Severe Glabellar Lines
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines.
- Trial name
- NCT06481475
- Testing
- YY003, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 153 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Moderate to Severe Glabellar Lines
DWP450 for Treating Moderate to Severe Glabellar Lines
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
- Trial name
- NCT06354127
- Testing
- DWP450, Botox®
- Where
- China
- Volunteers
- 473 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Masseter Muscle Prominence
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP EU P3 (NCT06068855)
- Testing
- BOTOX
- Where
- 27 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 249 people
- Sponsor
- AbbVie
Upper Limb Spasticity After Stroke
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
- Trial name
- DECIDE (NCT01239628)
- Where
- 11 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- Ipsen
Cervical Dystonia
Phase IV-Cervical Dystonia-INTEREST IN CD2
The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).
- Trial name
- INTEREST_INCD2 (NCT01753349)
- Testing
- Botulinum toxin type A
- Where
- 113 sites in United States, Algeria and 32 more
- Volunteers
- 1,050 people
- Sponsor
- Ipsen
Upper Limb Spasticity
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
- Trial name
- NCT06783114
- Testing
- Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®
- Where
- 24 sites in China
- Volunteers
- 254 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Upper and/or Lower Limb Focal Spasticity
A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity
The aim of this retrospective study is to describe the real-world outcomes with the treatment of adult patients with Dysport® injections for focal upper limb spasticity (ULS) and/or focal lower limb spasticity (LLS) in NHS…
- Trial name
- DYSCOVER (NCT04604379)
- Where
- 3 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Ipsen
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Lower Limb Spasticity
RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke
The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity.
- Trial name
- RELIEF (NCT02020980)
- Testing
- Botulinum toxin type A
- Where
- 28 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Ipsen
Post-Operative Atrial Fibrillation
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of…
- Trial name
- NCT03779841
- Testing
- AGN-151607
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 323 people
- Sponsor
- AbbVie
Glabellar Frown Lines
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06585696
- Testing
- CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX®
- Where
- China
- Volunteers
- 554 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Chronic Migraine
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
A study, multi-center, randomized, double-blind, placebo parallel-controlled method, will be carried out to evaluate the safety and efficacy of Botulinum Toxin Type A for injection (HengLi®) for prophylactic treatment with…
- Trial name
- NCT02291380
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 288 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd